Current and future state of T cell therapy manufacturing - Closing, automating and preparing

The commercial launch of approved cell therapies demonstrated to the industry and world alike the transformative impact they can have on a patient’s life and revolutionize the treatment of human disease. As a result, it is critical to evaluate and identify what is needed by the industry to support both the manufacture of small-scale autologous T cell therapies and adapt manufacturing processes towards large-scale allogeneic therapies that can impact a broader patient population. In this 90 minute symposium session, we will hear updates from industry leaders on the current status of their research in the T cell therapy manufacturing space and gain an understanding of the challenges associated with supporting conversion of autologous to allogeneic workflows. To present a complete overview, the panelists listed below will focus on the following: • Challenges of autologous neo-antigen TCR T cell therapy manufacturing • Closed modular cell therapy workflow solutions • Harnessing next-generation genome editing to develop allogeneic cell therapies • Improving therapeutic success through process development and allogeneic manufacturing.